Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

It’s hard to watch television without seeing advertisements for compounded GLP-1 weight-loss drugs cheaper than the authentic ...

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, launched a new advertising campaign on Friday ...

The spot makes lofty claims about weight-loss drugs offered by the telehealth company Hims & Hers, but says little about risks. By Dani Blum The first thing the ad shows is a scale. Over the ...

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Drug industry allies are calling out a Super Bowl ad touting its weight loss medications from telehealth company Hims & Hers, claiming the spot doesn't adequately disclose safety risks of these drugs.

A commercial airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs, as ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved ...